Patents by Inventor David Chi-cheong Wan

David Chi-cheong Wan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening
    Patent number: 9968616
    Abstract: Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (FABP4). The present invention provides a novel use of levofloxacin as an inhibitor of FABP4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases. The present invention further provides a method of using levofloxacin to inhibit FABP4, or to inhibit adipolysis in adipocytes.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: May 15, 2018
    Assignee: THE CHINESE UNIVERSITY OF HONG KONG
    Inventors: David Chi Cheong Wan, Yan Wang, Wai Kit Law, Jian Shu Hu, Tsz Ming Ip
  • DISCOVERY OF FDA-APPROVED DRUGS AS INHIBITORS OF FATTY ACID BINDING PROTEIN 4 USING MOLECULAR DOCKING SCREENING
    Publication number: 20160113937
    Abstract: Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (FABP4). The present invention provides a novel use of levofloxacin as an inhibitor of FABP4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases. The present invention further provides a method of using levofloxacin to inhibit FABP4, or to inhibit adipolysis in adipocytes.
    Type: Application
    Filed: October 23, 2015
    Publication date: April 28, 2016
    Inventors: David Chi Cheong WAN, Yan WANG, Wai Kit LAW, Jian Shu HU, Tsz Ming IP
  • Fluorescent proteins
    Patent number: 7335488
    Abstract: The present invention is directed to novel spontaneously fluorescent proteins having a unique chromophore formed from the amino acid sequence FR1R2R3F where R1 is Q or S; R2 is Y, W, F or H; and R3 is G, A or S (SEQ ID NO:34). The invention also encompasses the expression of nucleic acids that encode the proteins of the invention in a wide variety of engineered host cells, and the isolation of engineered proteins. In other embodiments, the invention comprises methods of use, generally including tagging a molecule or cell with the proteins of the invention by either chemical means or recombinant techniques.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: February 26, 2008
    Assignee: The Chinese University of Hong Kong
    Inventors: David Chi-Cheong Wan, Denis Tsz-Ming Ip
  • Use of transhinone derivates as cholinesterase inhibitors in treating related diseases
    Publication number: 20040191334
    Abstract: This present invention provides a new use of tanshinone derivatives as acetylcholinesterase inhibitors and in treating diseases associated with the depletion of acetylcholine such as cognitive impairment including Alzheimer's disease, insomnia, vascular dementia, memory loss, disorders of attention and other sleeping disorders. The active compounds commonly found in the root of Salvia genus, particularly Salvia miltiorrhiza, Danshen.
    Type: Application
    Filed: March 24, 2003
    Publication date: September 30, 2004
    Inventors: Pang-Chui Shaw, Michelle Tsz-Wan Ho, Kwok-Pui Fung, David Chi-Cheong Wan
  • Novel fluorescent proteins
    Publication number: 20030219814
    Abstract: The present invention is directed to novel spontaneously fluorescent proteins having a unique chromophore formed from the amino acid sequence FR1R2R3F where R1 is Q or S; R2 is Y, W, F or H; and R3 is G, A or S. The invention also encompasses the expression of nucleic acids that encode the proteins of the invention in a wide variety of engineered host cells, and the isolation of engineered proteins. In other embodiments, the invention comprises methods of use, generally including tagging a molecule or cell with the proteins of the invention by either chemical means or recombinant techniques.
    Type: Application
    Filed: April 2, 2003
    Publication date: November 27, 2003
    Applicant: THE CHINESE UNIVERSITY OF HONG KONG
    Inventors: David Chi-Cheong Wan, Denis Tsz-Ming Ip
  • Pharmaceutical compounds
    Patent number: 6235717
    Abstract: The present invention provides a compound of formula (I) or a salt thereof as well as methods of making and using same.
    Type: Grant
    Filed: July 3, 1995
    Date of Patent: May 22, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Johann Jakob Leban, Douglas Byron Sherman, James Frederick Sigafoos, Andreas Spaltenstein, Osvaldo Humberto Viveros, David Chi-cheong Wan